SSA
ZVRA icon

Schonfeld Strategic Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,824
Closed -$124K – 2754
2025
Q4 		$124K Buy
+13,824
New +$131K ﹤0.01% 1789
2023
Q1 		– Sell
-16,200
Closed -$74.4K – 2737
2022
Q4 		$74.4K Sell
16,200
-13,600
-46% -$69.1K ﹤0.01% 2227
2022
Q3 		$185K Sell
29,800
-9,800
-25% -$55.5K ﹤0.01% 2373
2022
Q2 		$177K Sell
39,600
-4,900
-11% -$22.3K ﹤0.01% 1945
2022
Q1 		$223K Buy
+44,500
New +$283K ﹤0.01% 1880

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Schonfeld Strategic Advisors's ZVRA Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 13,824 shares — an estimated $124K sold.

Schonfeld Strategic Advisors first reported a position in ZVRA in Q1 2022 and held it in 5 quarters. The position peaked at $223K in Q1 2022. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 13,824 Zevra Therapeutics shares in Q1 2026, an estimated $124K.
  • Schonfeld Strategic Advisors first reported a position in Zevra Therapeutics in Q1 2022 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Zevra Therapeutics position peaked at $223K in Q1 2022.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.